These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 16890673

  • 1. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 3. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV.
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [Abstract] [Full Text] [Related]

  • 7. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.
    Cancer; 2009 Aug 01; 115(15):3468-74. PubMed ID: 19484786
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May 01; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 01; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 13. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Dec 01; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 14. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.
    N Engl J Med; 2001 Sep 27; 345(13):948-55. PubMed ID: 11575286
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May 27; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.